Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

NCT07765524 is registered in ClinicalTrials.gov with Shenzhen Fosun Kairos Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07765524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07765524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
Lead sponsor
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
September 30, 2029
Enrollment
32 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

primary light chain (al) amyloidosis